Form 8-K - Current report:
SEC Accession No. 0000950170-22-001956
Filing Date
2022-02-24
Accepted
2022-02-24 16:01:49
Documents
14
Period of Report
2022-02-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cycn-20220224.htm   iXBRL 8-K 61480
2 EX-99.1 cycn-ex99_1.htm EX-99.1 39370
3 GRAPHIC img121346916_0.jpg GRAPHIC 16106
  Complete submission text file 0000950170-22-001956.txt   258405

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cycn-20220224_pre.xml EX-101.PRE 11604
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cycn-20220224.xsd EX-101.SCH 2503
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cycn-20220224_lab.xml EX-101.LAB 18619
8 EXTRACTED XBRL INSTANCE DOCUMENT cycn-20220224_htm.xml XML 4878
Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Filer) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38787 | Film No.: 22670800
SIC: 2834 Pharmaceutical Preparations